{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"30","upperLimit":"86","value":"62"},{"groupId":"OG001","lowerLimit":"32","upperLimit":"100","value":"100"}]}],"title":"Complete Response"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3","upperLimit":"50","value":"15"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"68","value":"0"}]}],"title":"Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3","upperLimit":"50","value":"15"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"68","value":"0"}]}],"title":"Stable Disease"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1","upperLimit":"42","value":"8"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"68","value":"0"}]}],"title":"Progressive Disease"}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"description":"Clinical response at the recommended phase 2 dose per RECIST v1.1 Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\<10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression). Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients undergo pelvic EBRT or IMRT 5 days per week for 5 weeks (25 fractions) with a 3-day boost in week 6, and 1 or 2 applications of LDR brachytherapy in week 6 or 5 fractions of HDR brachytherapy at week 4 or 5. Patients also receive triapine IV over 120 minutes on day 1 and PO on days 2-5, 8-12, 15-19, 22-26, and 29-33 within 90 minutes after pelvic irradiation, and cisplatin IV over 60-120 minutes once weekly for 5 weeks (days 2, 9, 16, 23, and 30). Treatment continues in the absence of disease progression or unacceptable toxicity. Patients may receive a 6th cycle of cisplatin IV during the parametrial boost or any make-up radiation treatment in a sixth week of external beam radiotherapy. Patients undergo the collection of blood samples on study and undergo MRI and FDG-PET/CT during follow-up.\n\nBiospecimen Collection: Undergo collection of blood samples\n\nBrachytherapy: Undergo LDR brachytherapy\n\nCisplatin: Given IV\n\nComputed Tomography: Undergo FDG-PET/CT\n\nExternal Beam Radiation Therapy: Undergo pelvic EBRT\n\nFludeoxyglucose F-18: Undergo FDG-PET/CT\n\nHigh-Dose Rate Brachytherapy: Undergo HDR brachytherapy\n\nIntensity-Modulated Radiation Therapy: Undergo IMRT\n\nMagnetic Resonance Imaging: Undergo MRI\n\nPharmacological Study: Correlative studies\n\nPositron Emission Tomography: Undergo FDG-PET/CT\n\nTriapine: Given IV and PO","id":"OG000","title":"Triapine (100mg) + Chemoradiation)"},{"description":"Patients undergo pelvic EBRT or IMRT 5 days per week for 5 weeks (25 fractions) with a 3-day boost in week 6, and 1 or 2 applications of LDR brachytherapy in week 6 or 5 fractions of HDR brachytherapy at week 4 or 5. Patients also receive triapine IV over 120 minutes on day 1 and PO on days 2-5, 8-12, 15-19, 22-26, and 29-33 within 90 minutes after pelvic irradiation, and cisplatin IV over 60-120 minutes once weekly for 5 weeks (days 2, 9, 16, 23, and 30). Treatment continues in the absence of disease progression or unacceptable toxicity. Patients may receive a 6th cycle of cisplatin IV during the parametrial boost or any make-up radiation treatment in a sixth week of external beam radiotherapy. Patients undergo the collection of blood samples on study and undergo MRI and FDG-PET/CT during follow-up.","id":"OG001","title":"Triapine (150mg) + Chemoradiation)"}],"paramType":"NUMBER","populationDescription":"Patients who received at least 3 weeks of therapy (cisplatin + triapine) and have had their disease re-evaluated (with a 3 month post treatment PET-CT) will be considered evaluable for response. (Note: Patients who exhibit objective disease progression prior to the end of cycle 1 will also be considered evaluable.)","reportingStatus":"POSTED","timeFrame":"3 months post-treatment","title":"Clinical Overall Response Rate","type":"SECONDARY","unitOfMeasure":"percentage response evaluable patient"}